Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Medication Adherence
Interventions: Survey; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Davis, California • Indianapolis, Indiana • Minneapolis, Minnesota + 5 more

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, RO4998452; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 8 more

Conditions: Traumatic Lacerations or Surgical Incisions
Interventions: BondEase, CWCD; Device · Procedure
Lead sponsor: OptMed, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Orlando, Florida • Chicago, Illinois • Chevy Chase, Maryland + 3 more

Conditions: Pregnancy Related
Interventions: Elafibranor; Drug
Lead sponsor: Ipsen; Industry
Eligibility: Female only
Enrollment: 3 participants
Timeline: 2026 – 2039
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Brentwood, Tennessee

Conditions: Dry Eye Syndrome
Interventions: Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle); Drug
Lead sponsor: Mitotech, SA; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more

Conditions: Acne Vulgaris
Interventions: S6G5T-3, S6G5T-8; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 9 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Contraception
Interventions: ESS310 (BAY1454032); Device
Lead sponsor: Bayer; Industry
Eligibility: 21 Years to 44 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 16
States / cities: Glendale, Arizona • Phoenix, Arizona • Colorado Springs, Colorado + 12 more

Conditions: Asthma
Interventions: AS MDI, Proventil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Winter Park, Florida • North Dartmouth, Massachusetts • St Louis, Missouri + 2 more

Conditions: Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions: Non-interventional observational prospective cohort study; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis, Mild Cognitive Impairment
Interventions: CRT, CBT, Modifiable lifestyle factors, Usual care Psychoeducation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 106
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan, Tadalafil, Selexipag; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Multiple Forms of Child Abuse, Domestic Violence
Interventions: Adult and Child Survivor Centered Approach; Other
Lead sponsor: University of Kansas; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Birmingham, Alabama • Berkeley, California • Los Angeles, California + 22 more

Conditions: Irritable Bowel Syndrome
Interventions: True avoidance diet, Sham avoidance diet; Other
Lead sponsor: IBS-80, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: North Wales, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Alzheimer Disease
Interventions: sabirnetug (ACU193), Sabirnetug + rHuPH20; Drug · Combination Product
Lead sponsor: Acumen Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Interventions: PRT3789, Docetaxel; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 20
States / cities: Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: AZD4831, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Arteriovenous Fistula
Interventions: SRM003, Participating Site's standard practice; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 41 more

Conditions: Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis, Rheumatoid Arthritis
Interventions: Augment® Injectable Bone Graft, Autologous bone graft; Device · Procedure
Lead sponsor: BioMimetic Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 20
States / cities: Tucson, Arizona • San Francisco, California • Glenview, Illinois + 16 more

Conditions: Influenza, Healthy Volunteers
Interventions: Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more

Conditions: Overactive Bladder, Parkinson Disease
Interventions: mirabegron, Exercise-based behavioral therapy; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Decatur, Georgia • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Alpha₁-Antitrypsin Deficiency
Interventions: Liquid Alpha₁-PI, Prolastin-C; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Denver, Colorado • Gainesville, Florida • Miami, Florida + 3 more

Search by objective public record fields.

Perspectives on Prophylactic Antibiotic Use in Dermatologic Surgery

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Safety and Efficacy Study of BondEase to Treat Traumatic Lacerations and Surgical Incisions

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

Study of SkQ1 as Treatment for Dry-eye Syndrome

A Study of S6G5T3 in the Treatment of Acne Vulgaris

Essure (Model ESS310) Placement Rate Study

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

A Pilot Randomized Controlled Trial: CoINTEGRATE

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Quality Improvement Center on Domestic Violence in Child Welfare

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

IBS Skin Patch Test Food Allergy Study

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access

Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency